Jaguar Health, Inc. Announces Reverse Stock Split
Jaguar Health (NASDAQ:JAGX) has announced a 1-for-25 reverse stock split effective March 24, 2025. The company's common stock will continue trading on the Nasdaq Capital Market under the symbol 'JAGX' with a new CUSIP number 47010C888.
The reverse split was approved by stockholders at a March 2025 Special Meeting, requiring majority approval from holders of Common Stock and Series J Perpetual Preferred Stock. According to CEO Lisa Conte, this strategic move aims to maintain Nasdaq listing compliance and achieve a more attractive share price and outstanding share count for institutional investors.
No fractional shares will be issued, with cash payments provided instead. Equiniti Trust Company, will serve as the exchange agent, managing the certificate exchange process for stockholders of record. Stockholders with shares in brokerage accounts or 'street name' require no action.
Jaguar Health (NASDAQ:JAGX) ha annunciato un frazionamento azionario inverso di 1 per 25 che entrerà in vigore il 24 marzo 2025. Le azioni ordinarie della società continueranno a essere negoziate sul Nasdaq Capital Market con il simbolo 'JAGX' e un nuovo numero CUSIP 47010C888.
Il frazionamento inverso è stato approvato dagli azionisti in una Riunione Straordinaria di marzo 2025, richiedendo l'approvazione della maggioranza da parte dei detentori di azioni ordinarie e di azioni privilegiate perpetue di Serie J. Secondo l'amministratore delegato Lisa Conte, questa mossa strategica mira a mantenere la conformità con le norme di quotazione del Nasdaq e a raggiungere un prezzo delle azioni più attraente e un numero di azioni in circolazione più favorevole per gli investitori istituzionali.
Non verranno emesse azioni frazionarie, ma saranno forniti pagamenti in contante. Equiniti Trust Company agirà come agente di cambio, gestendo il processo di scambio dei certificati per gli azionisti registrati. Gli azionisti con azioni in conti di intermediazione o 'nome di strada' non richiedono alcuna azione.
Jaguar Health (NASDAQ:JAGX) ha anunciado un split inverso de acciones de 1 por 25 que entrará en vigor el 24 de marzo de 2025. Las acciones ordinarias de la compañía continuarán cotizando en el Nasdaq Capital Market bajo el símbolo 'JAGX' con un nuevo número CUSIP 47010C888.
El split inverso fue aprobado por los accionistas en una Junta Especial de marzo de 2025, requiriendo la aprobación de la mayoría de los tenedores de acciones ordinarias y de acciones preferentes perpetuas de la Serie J. Según la CEO Lisa Conte, este movimiento estratégico tiene como objetivo mantener el cumplimiento de la cotización en el Nasdaq y lograr un precio de acción más atractivo y un número de acciones en circulación más favorable para los inversores institucionales.
No se emitirán acciones fraccionarias, sino que se proporcionarán pagos en efectivo. Equiniti Trust Company actuará como agente de intercambio, gestionando el proceso de intercambio de certificados para los accionistas registrados. Los accionistas con acciones en cuentas de corretaje o 'nombre en la calle' no requieren ninguna acción.
재규어 헬스 (NASDAQ:JAGX)는 2025년 3월 24일부터 1대 25의 액면분할을 시행한다고 발표했습니다. 회사의 보통주는 'JAGX' 기호로 나스닥 자본 시장에서 계속 거래되며, 새로운 CUSIP 번호는 47010C888입니다.
이번 액면분할은 2025년 3월 특별 회의에서 주주들의 승인을 받아 이루어졌으며, 보통주 및 J 시리즈 영구 우선주 보유자들로부터 과반수의 승인이 필요했습니다. CEO 리사 콘트에 따르면, 이번 전략적 결정은 나스닥 상장 요건을 유지하고 기관 투자자들에게 더 매력적인 주가와 유통 주식 수를 달성하기 위한 것입니다.
분할된 주식은 발행되지 않으며, 대신 현금 지급이 이루어집니다. 에퀴니티 트러스트 컴퍼니가 교환 대행사로서 등록된 주주들의 증서 교환 과정을 관리합니다. 중개 계좌 또는 '거리 이름'으로 주식을 보유한 주주들은 별도의 조치를 취할 필요가 없습니다.
Jaguar Health (NASDAQ:JAGX) a annoncé un regroupement d'actions de 1 pour 25 qui prendra effet le 24 mars 2025. Les actions ordinaires de la société continueront à être négociées sur le marché Nasdaq Capital sous le symbole 'JAGX' avec un nouveau numéro CUSIP 47010C888.
Le regroupement a été approuvé par les actionnaires lors d'une Assemblée Générale Extraordinaire en mars 2025, nécessitant l'approbation de la majorité des détenteurs d'actions ordinaires et d'actions privilégiées perpétuelles de la Série J. Selon la PDG Lisa Conte, ce mouvement stratégique vise à maintenir la conformité avec les exigences de cotation du Nasdaq et à atteindre un prix d'action plus attrayant ainsi qu'un nombre d'actions en circulation plus favorable pour les investisseurs institutionnels.
Aucune action fractionnée ne sera émise, des paiements en espèces seront fournis à la place. Equiniti Trust Company agira en tant qu'agent d'échange, gérant le processus d'échange de certificats pour les actionnaires enregistrés. Les actionnaires détenant des actions dans des comptes de courtage ou sous 'nom de rue' n'ont besoin d'aucune action.
Jaguar Health (NASDAQ:JAGX) hat einen Reverse-Split von 1 zu 25 angekündigt, der am 24. März 2025 in Kraft tritt. Die Stammaktien des Unternehmens werden weiterhin unter dem Symbol 'JAGX' am Nasdaq Capital Market gehandelt, mit einer neuen CUSIP-Nummer 47010C888.
Der Rücksplit wurde von den Aktionären auf einer außerordentlichen Hauptversammlung im März 2025 genehmigt, wobei eine Mehrheit der Inhaber von Stammaktien und der Serie J perpetuellen Vorzugsaktien erforderlich war. Laut CEO Lisa Conte zielt dieser strategische Schritt darauf ab, die Einhaltung der Nasdaq-Listing-Vorgaben aufrechtzuerhalten und einen attraktiveren Aktienkurs sowie eine günstigere Anzahl ausstehender Aktien für institutionelle Investoren zu erreichen.
Es werden keine Bruchstücke von Aktien ausgegeben, stattdessen werden Barzahlungen bereitgestellt. Die Equiniti Trust Company wird als Austauschagentur fungieren und den Austauschprozess für die registrierten Aktionäre verwalten. Aktionäre mit Aktien in Brokerkonten oder 'Straßennamen' müssen keine Maßnahmen ergreifen.
- Maintains Nasdaq listing compliance
- Potential to attract institutional investors
- Reverse stock split indicates share price weakness
- Significant share consolidation (25:1 ratio) may signal financial distress
- No fundamental value change for shareholders
Insights
Jaguar Health's announcement of a 1-for-25 reverse stock split represents a significant defensive financial maneuver primarily aimed at maintaining Nasdaq compliance. With shares currently trading at
The substantial 1:25 ratio is particularly concerning, as it suggests severe historical share price deterioration. This is not a minor adjustment but rather a dramatic consolidation needed to lift the share price to approximately
While CEO Lisa Conte frames this as potentially attracting institutional investors through a higher share price, this perspective is overly optimistic. Institutional investors evaluate fundamentals beyond nominal share prices, and the need for such an extreme reverse split often signals underlying business challenges rather than opportunity.
For existing shareholders, while their proportional ownership remains unchanged, the optics and historical precedent are concerning. Companies implementing substantial reverse splits frequently continue to experience share price deterioration after the adjustment. The preservation of Nasdaq listing does maintain trading liquidity and market visibility, but this action addresses a symptom (low share price) rather than underlying causes of the company's financial situation.
Reverse split approved at March 2025 Special Meeting of Stockholders
Shares of Jaguar Health common stock to begin trading on split-adjusted basis on March 24, 2025
SAN FRANCISCO, CA / ACCESS Newswire / March 18, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the Company will effect a reverse stock split of its issued and outstanding voting common stock ("Common Stock"), at an exchange ratio of 1-for-25, on Monday, March 24, 2025 (the "Effective Date") in order to support the Company's compliance with Nasdaq's listing standards. The Company's Common Stock will begin trading on a split-adjusted basis when the market opens on the Effective Date and will remain listed on The Nasdaq Capital Market under the symbol "JAGX". The new CUSIP number for the Company's Common Stock following the reverse stock split is 47010C888.
"Jaguar's board of directors has determined that effecting a reverse stock split at this time will, in addition to supporting the Company's compliance with Nasdaq's listing standards, provide Jaguar with the opportunity to achieve a share price and outstanding share count that is more attractive to institutional investors," said Lisa Conte, Jaguar's president and CEO.
The effectuation of the reverse stock split follows the approval of a proposal submitted to Jaguar stockholders at a Special Meeting of Stockholders (the "Special Meeting"). This proposal, which was approved by the affirmative vote of the holders of a majority in voting power of the votes cast affirmatively or negatively (excluding abstention and broker non-votes) on such proposal by shares of Jaguar Common Stock and Series J Perpetual Preferred Stock of the Company outstanding as of the record date for the Special Meeting, is described in detail in the Company's definitive proxy statement on Schedule 14A relating to the Special Meeting filed with the Securities and Exchange Commission (the "SEC") on February 24, 2025. Stockholders may obtain a free copy of the proxy statement and other documents filed by Jaguar with the SEC at http://www.sec.gov. The proxy statement is also available on the Company's corporate website.
When the reverse stock split becomes effective, every 25 (twenty-five) shares of the Company's Common Stock immediately prior to the Effective Date shall automatically be reclassified into one (1) share of Common Stock, without any change in the par value per share, and this change will be reflected on Nasdaq's website and other stock quote platforms. No fractional shares will be issued as a result of the reverse stock split. Stockholders who otherwise would be entitled to receive a fractional share in connection with the reverse stock split will receive a cash payment in lieu thereof.
Equiniti Trust Company, LLC is acting as exchange agent for the reverse stock split and will send instructions to stockholders of record who hold stock certificates regarding the exchange of their certificates for post-reverse stock split shares of Common Stock. Stockholders who hold their shares in brokerage accounts or "street name" are not required to take any action to effect the exchange of their shares.
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that the Company's Common Stock will begin trading on a split-adjusted basis when the market opens on the Effective Date, and the expectation that effecting a reverse stock split may provide Jaguar with the opportunity to achieve a share price and outstanding share count that is more attractive to institutional investors. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
hello@jaguar.health
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View the original press release on ACCESS Newswire
FAQ
When will JAGX's 1-for-25 reverse stock split take effect?
What happens to fractional shares in JAGX's reverse stock split?
Why is Jaguar Health implementing a reverse stock split?
Will JAGX's stock symbol change after the reverse split?
